Aeon Biopharma Reports FY GAAP EPS of -$3.95, Cash Reserves Sufficient Through Q3 2026

Aeon Biopharma reported a GAAP EPS of -$3.95 for FY. The company had cash and cash equivalents of $3 million as of December 31, 2025. Including the $4.2 million in proceeds from the second closing of the PIPE financing in January 2026, the company expects to have sufficient funds to support its operating plan into Q3 2026.